Participants 18 years or older

Participants who signed an informed consent

Participants diagnosed with PsA as per the criteria of the Classification of Psoriatic Arthritis (CASPAR) Study Group18

Participants naïve of abatacept and who at their physician's discretion initiate abatacept

Participants meeting criteria for abatacept treatment for PsA as specified in the German label

Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants